Exhibit 99.3
LinkedIn posting announcing positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat co-administered with approved IPF therapies
Target Posting Date: January 12, 2022
Post Text
Today we announced the successful completion of a phase 1 drug-drug interaction clinical study that evaluated co-administration of cudetaxestat with either of two approved therapies for idiopathic pulmonary fibrosis. Cudetaxestat is our investigational non-competitive autotaxin inhibitor in clinical development for IPF. Find out more by clicking on the link to our news release: LINK.
Hashtags: #lungfibrosis #fibrosis #autotaxin #clinicalresearch #IPF #clinicaldevelopment
Graphic